Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neoadjuvant therapy Clear all
Withdrawn Phase 2 Interventional

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

NCT03325465
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 3 Interventional

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

NCT00003937
View directory record Official record
Conditions
Cardiac Toxicity, Sarcoma
Interventions
cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, conventional surgery
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
132
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Nov 6, 2026, 9:45 PM EST
Active, not recruiting Phase 2 Interventional

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

NCT04123379
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
Nivolumab, BMS-813160, BMS-986253
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Recruiting Phase 2 Interventional

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

NCT06623656
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Early Phase 1 Interventional Results available

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7, Stage IIA Lung Carcinoma, Stage IIIA Lung Carcinoma
Interventions
Vitamin A Compound, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Nov 6, 2026, 9:45 PM EST
Active, not recruiting Not applicable Interventional

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

NCT04204811
View directory record Official record
Conditions
Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Fallopian Tube Cancer
Interventions
Prehabilitation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Phase 2 Interventional Results available

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

NCT01359007
View directory record Official record
Conditions
Adenocarcinoma of Pancreas
Interventions
Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer

NCT00004103
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Nov 6, 2026, 9:45 PM EST
Completed Not applicable Interventional Results available

Preoperative Exercise in Pancreatic Cancer

NCT02648880
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Exercise program, Standard Care
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Phase 2 Interventional Results available

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

NCT00537823
View directory record Official record
Conditions
Colorectal Cancer, Metastases
Interventions
Cetuximab, Bevacizumab, Leucovorin, Oxaliplatin, Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 2 Interventional Results available

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

NCT01401959
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 2 Interventional Results available

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

NCT03259035
View directory record Official record
Conditions
Rectal Cancer
Interventions
Folfox Protocol, Capox
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Orange, California • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Completed Not applicable Interventional Results available

Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms

NCT01110174
View directory record Official record
Conditions
Breast Cancer
Interventions
HD PET/CT
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Not applicable Interventional Results available

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

NCT02256982
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Cisplatin, Surgery, Radiation
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Not applicable Interventional

Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

NCT06122480
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease
Interventions
Surgery
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Active, not recruiting Phase 2 Interventional

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT03708224
View directory record Official record
Conditions
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Atezolizumab, Tocilizumab, Tiragolumab
Biological
Lead sponsor
Alain Algazi
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Completed Not applicable Interventional

Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer

NCT01830582
View directory record Official record
Conditions
Rectal Cancer
Interventions
Advanced MR Imaging
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 2 Interventional Results available

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Recruiting Phase 3 Interventional

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

NCT06507618
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Tamoxifen, Letrozole, Anastrozole, or Exemestane
Drug
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
6
States / cities
New Haven, Connecticut • Charlottesville, Virginia • Culpeper, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Completed Phase 2 Interventional Results available

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

NCT00017563
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, mitoxantrone hydrochloride, conventional surgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 6, 2026, 9:45 PM EST
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00262925
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
alemtuzumab, asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
58
States / cities
Aurora, Illinois • Chicago, Illinois • Joliet, Illinois + 43 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Nov 6, 2026, 9:45 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
64
States / cities
Dothan, Alabama • Scottsdale, Arizona • Sun City, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 6, 2026, 9:45 PM EST
Withdrawn Phase 2 Interventional

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

NCT05415917
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine and Capecitabine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 6, 2026, 9:45 PM EST